Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sinovac quadrivalent influenza vaccine
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Sinovac quadrivalent influenza vaccine (QIV) is an inactivated, split-virion biologic developed by Sinovac Biotech Co., Ltd. for the prevention of seasonal influenza. It contains inactivated influenza virus strains derived from World Health Organization (WHO) recommendations, providing protection against four distinct strains: two influenza A subtypes and two influenza B lineages. The vaccine works by targeting the viral hemagglutinin (HA) protein to induce the production of hemagglutination inhibition (HI) antibodies. It was evaluated in a Phase III clinical trial in Chile, conducted in collaboration with the Pontificia Universidad Católica de Chile, where it demonstrated non-inferior immunogenicity and a comparable safety profile to the licensed comparator VaxigripTetra in individuals aged 3 years and older during the 2023 Southern Hemisphere influenza season.
- Brand names
- Anflu
- Other names
- Sinovac QIVTetravalent influenza vaccine (Sinovac)Influenza Vaccine, Inactivated, Quadrivalent (Sinovac)
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Sinovac quadrivalent influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinovac quadrivalent influenza vaccine.